Altimmune, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a $12.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Patrick Trucchio has given his Buy rating due to a combination of factors including Altimmune’s strategic leadership changes and promising clinical data. The recent appointments of a new Chief Medical Officer and Chief Commercial Officer have sharpened the company’s focus on advancing its clinical and commercial strategies, particularly for the metabolic dysfunction-associated steatohepatitis (MASH) program.
Altimmune’s lead candidate, pemvidutide, is highlighted for its dual GLP-1/glucagon mechanism, which shows promising results in addressing metabolic and hepatic disease drivers. The company is preparing for significant upcoming catalysts, including a pivotal 48-week readout from the Phase 2b IMPACT trial. This data is expected to support a robust Phase 3 strategy, potentially reducing reliance on biopsies and incorporating non-invasive tests. The valuation of Altimmune is supported by a risk-adjusted methodology, with a high probability of success for pemvidutide in MASH and obesity, leading to a price target of $12.
Trucchio covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Precision BioSciences, and Aligos Therapeutics. According to TipRanks, Trucchio has an average return of 29.8% and a 51.85% success rate on recommended stocks.